Kv1.5 open channel block by the antiarrhythmic drug disopyramide:: Molecular determinants of block

被引:16
作者
Arechiga, Ivan A. [1 ]
Barrio-Echavarria, Gabriel F. [1 ]
Rodriguez-Menchaca, Aldo A. [1 ]
Moreno-Galindo, Eloy G. [1 ]
Decher, Niels [2 ]
Tristani-Firouzi, Martin [3 ]
Sanchez-Chapula, Jose A. [1 ]
Navarro-Polanco, Ricardo A. [1 ]
机构
[1] Univ Colima, Ctr Invest Biomed, Unidad Invest Carlos Mendez, Colima, Mexico
[2] Univ Marburg, Inst Physiol, Marburg, Germany
[3] Univ Utah, Dept Pediat Cardiol, Salt Lake City, UT 84132 USA
关键词
potassium channel; ultra rapid delayed rectifier; Kv1.5; antiarrhythmic; disopyramide;
D O I
10.1254/jphs.08084FP
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Kv1.5 is considered to be a potential molecular target for treatment of atrial fibrillation or flutter. Disopyramide is widely used in the treatment of atrial flutter and/or atrial fibrillation. The present study was undertaken to characterize the effects of disopyramide on currents mediated by Kv1.5 channels and to determine the putative binding site involved in the inhibitory effects of disopyramide. Experiments were carried out on wild-type and site directed mutated hKv1.5 channels expressed on HEK 293 cells using the patch-clamp technique. Disopyramide acting from the cytoplasmic side of the membrane produced blocking effects on Kv1.5 that exhibited several features typical of an open channel blocker. Ala-scanning mutagenesis of the Kv1.5 pore domain combined with macroscopic current analysis Suggested that disopyramide interacted only with the Val512 residue that faces to the central cavity of the channel. Mutation of this key residue to Ala caused marked change in the IC50 of disopyramide (22-fold). The single interaction between disopyramide and Val512 in the PVP region is able to change the mechanism of channel closure, reproducing the "foot-in-the-door" phenomenon.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 43 条
[2]   Two functionally distinct subsites for the binding of internal blockers to the pore of voltage-activated K+ channels [J].
Baukrowitz, T ;
Yellen, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (23) :13357-13361
[3]   Early class III drugs for the treatment of atrial fibrillation -: Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat [J].
Blaauw, Y ;
Gögelein, H ;
Tieleman, RG ;
van Hunnik, A ;
Schotten, U ;
Allessie, MA .
CIRCULATION, 2004, 110 (13) :1717-1724
[4]   Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5) [J].
Caballero, R ;
Moreno, I ;
González, T ;
Valenzuela, C ;
Tamargo, J ;
Delpón, E .
CARDIOVASCULAR RESEARCH, 2002, 56 (01) :104-117
[5]   Advances in antiarrhythmic drug treatment of atrial fibrillation: Where do we stand now? [J].
Camm, AJ ;
Savelieva, I .
HEART RHYTHM, 2004, 1 (02) :244-246
[6]   USE-DEPENDENT BLOCK OF THE DELAYED K+ CURRENT IN RABBIT VENTRICULAR MYOCYTES [J].
CARMELIET, E .
CARDIOVASCULAR DRUGS AND THERAPY, 1993, 7 :599-604
[7]   Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel [J].
Casis, O ;
Sánchez-Chapula, JA .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 (04) :521-526
[8]   Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility [J].
Choudhury, A ;
Lip, GYH .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (07) :841-855
[9]   Molecular basis for Kv1.5 channel block -: Conservation of drug binding sites among voltage-gated K+ channels [J].
Decher, N ;
Pirard, B ;
Bundis, F ;
Peukert, S ;
Baringhaus, KH ;
Busch, AE ;
Steinmeyer, K ;
Sanguinetti, MC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (01) :394-400
[10]   Binding site of a novel Kv1.5 blocker: A "foot in the door" against atrial fibrillation [J].
Decher, Niels ;
Kumar, Pradeep ;
Gonzalez, Teresa ;
Pirard, Bernard ;
Sanguinetti, Michael C. .
MOLECULAR PHARMACOLOGY, 2006, 70 (04) :1204-1211